Suppr超能文献

女性银屑病管理的临床考量

Clinical considerations for the management of psoriasis in women.

作者信息

Gottlieb Alice B, Ryan Caitriona, Murase Jenny E

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

Blackrock Clinic and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.

出版信息

Int J Womens Dermatol. 2019 Apr 10;5(3):141-150. doi: 10.1016/j.ijwd.2019.04.021. eCollection 2019 Jul.

Abstract

The burden of psoriasis is particularly high for women, who report lower levels of happiness (women: 18.5%; men: 11.3% lower vs. general population) and are more likely to experience stress (women: > 60%; men: 42%), loneliness (women: 25-28%; men: 19-24%), stigmatization (Feelings of Stigmatization Questionnaire score; women: 93.2; men: 78.0), and reduced sexual activity (women: 33%; men: 19%) compared with men. The onset of psoriasis is bimodal, with one incidence peak (15-30 years) that coincides with the prime reproductive age for women, which poses specific challenges for their treatment. However, well-established guidelines for the treatment of women of childbearing age are lacking. Many women experience stabilization (21%) or improvement (55%) of their skin during pregnancy, but up to a quarter can experience disease worsening, and postpartum flares are common (> 50%). Therefore, balancing the risk of treatment with the risk of uncontrolled disease is important. Because half of pregnancies are unplanned, the implications of therapeutic options must be considered for all women with psoriasis who are sexually active, irrespective of intentions to start a family. Timely initiation of these discussions by health care professionals is paramount to prevent unintentional toxicity to the developing fetus. For example, acitretin, methotrexate, and oral psoralen/ultraviolet A are all contraindicated in pregnancy. Reassuringly, safety data for other psoriasis treatments during pregnancy are increasingly available, particularly for anti-tumor necrosis factor therapies. Despite encouraging data from pregnancy exposure registries and clinical studies now being included in anti-tumor necrosis factor drug labels, comfort with prescribing these therapies to pregnant women remains low (U.S. dermatologists: 21%; EU-5 dermatologists: 10%). In this article, we review issues specific to treating women of childbearing age with psoriasis and highlight the need for treatment guidelines to ensure consistent care and optimal outcomes for these patients.

摘要

银屑病给女性带来的负担尤为沉重,她们的幸福感较低(女性:18.5%;男性:比普通人群低11.3%),更易经历压力(女性:>60%;男性:42%)、孤独感(女性:25 - 28%;男性:19 - 24%)、被污名化(污名化感受问卷得分;女性:93.2;男性:78.0),与男性相比,性活动减少(女性:33%;男性:19%)。银屑病的发病呈双峰模式,其中一个发病高峰(15 - 30岁)与女性的最佳生育年龄重合,这给她们的治疗带来了特殊挑战。然而,目前缺乏针对育龄期女性的成熟治疗指南。许多女性在孕期皮肤会稳定(21%)或改善(55%),但高达四分之一的女性病情可能恶化,产后病情复发也很常见(>50%)。因此,平衡治疗风险与疾病失控风险很重要。由于半数怀孕是意外怀孕,对于所有有性活动的银屑病女性,无论其生育意愿如何,都必须考虑治疗方案的影响。医疗保健专业人员及时开展这些讨论对于防止对发育中的胎儿造成意外毒性至关重要。例如,阿维A、甲氨蝶呤和口服补骨脂素/紫外线A在孕期均为禁忌。令人欣慰的是,关于孕期其他银屑病治疗的安全性数据越来越多,尤其是抗肿瘤坏死因子疗法。尽管来自孕期暴露登记处和临床研究的令人鼓舞的数据现已纳入抗肿瘤坏死因子药物标签中,但对孕妇使用这些疗法的放心程度仍然较低(美国皮肤科医生:21%;欧盟五国皮肤科医生:10%)。在本文中,我们回顾了治疗育龄期银屑病女性的特定问题,并强调需要治疗指南以确保为这些患者提供一致的护理和最佳治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb39/6637092/4fe4979489ed/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验